🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

HCP Amends And Restates Credit Facility, Boosts Strength

Published 05/27/2019, 10:51 PM
Updated 07/09/2023, 06:31 AM
LAMR
-
DOC
-
PSB
-
DRE
-

HCP Inc. (NYSE:HCP) recently boosted its financial position by closing an amended and restated credit agreement. The move offers greater flexibility to the company as it provides a $2.5-billion unsecured revolving credit facility and a new $250-million unsecured term loan facility.

Specifically, with this move, the size of the unsecured revolving credit facility has been increased to $2.5 billion from $2 billion, while the maturity date of the unsecured revolving credit facility has been extended to May 23, 2023, with two 6-month extension options.

Further, it helped in lowering the borrowing costs. The unsecured revolving credit facility bears interest at a rate per annum equal to LIBOR plus 82.5 basis points as of closing, while the facility fee on the entire revolving commitment is 15 basis points per annum. These are based on the company’s current credit ratings. Also, a sustainability-linked pricing grid is incorporated with the unsecured revolving credit facility. This will lower the borrowing spread when certain benchmarks are achieved each year. In addition, the unsecured term loan facility includes a 90-day delayed-draw feature and was undrawn at closing.

The decrease in borrowing costs is anticipated to reduce the company’s annualized interest expense. The move will improve the company’s cash flow and alleviate its bottom-line pressure as well.

Moreover, the company has the option to enjoy more borrowing capacity, by up to an additional $750 million, for a maximum borrowing of $3.5 billion. This is subject to certain customary conditions.

The amendment, which boosts its financial flexibility and future investment activities, highlights lenders' confidence in the company. Extending maturities provide the company ample scope for deploying capital for long-term growth opportunities and carrying out acquisition initiatives.

Notably, HCP remains on track to execute portfolio-repositioning measures in a bid to improve the quality of the senior housing portfolio and lower operator concentration. Also, investments in the medical office and life science real estate properties are expected to drive long-term growth. Furthermore, the company is making diligent efforts to strengthen its balance sheet. However, the dilutive impact on earnings in the near term from asset disposals is unavoidable. In addition, choppy senior housing fundamentals and elevated supply in some of the company’s markets will hurt HCP’s results in the upcoming quarters.

HCP currently carries a Zacks Rank #3 (Hold). In the past six months, shares of the company have outperformed the industry. While the stock has gained 10.5%, the industry has increased 9.6% during this period.



Stocks to Consider

Some better-ranked stocks from the real-estate space include Duke Realty Corp. (NYSE:DRE) , Lamar Advertising Company (NASDAQ:LAMR) and PS Business Parks, Inc. (NYSE:PSB) , each carrying a Zacks Rank of 2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Duke Realty’s Zacks Consensus Estimate for 2019 funds from operations (FFO) per share moved marginally north to $1.41 in the past week.

Lamar’s FFO per share estimates for the current year remained unchanged at $5.81 over the past week.

PS Business Parks’ Zacks Consensus Estimate for the ongoing year’s FFO per share moved up slightly to $6.61 in the past month.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Lamar Advertising Company (LAMR): Free Stock Analysis Report

Duke Realty Corporation (DRE): Free Stock Analysis Report

HCP, Inc. (HCP): Free Stock Analysis Report

PS Business Parks, Inc. (PSB): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.